F
Fred Hardwicke
Researcher at Texas Tech University Health Sciences Center
Publications - 28
Citations - 369
Fred Hardwicke is an academic researcher from Texas Tech University Health Sciences Center. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 7, co-authored 28 publications receiving 318 citations. Previous affiliations of Fred Hardwicke include Texas Tech University.
Papers
More filters
Journal ArticleDOI
Management of hand-foot syndrome induced by capecitabine.
TL;DR: Treatment interruption or dose reduction remain the only methods shown to effectively manage HFS, but supportive measures to reduce pain and discomfort and prevent secondary infection are very important.
Journal ArticleDOI
Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer†
Maurizio Chiriva-Internati,Yuefei Yu,Leonardo Mirandola,Nicholas D'Cunha,Fred Hardwicke,Martin J. Cannon,Everardo Cobos,W. Martin Kast,W. Martin Kast +8 more
TL;DR: This work investigated the expression of the cancer/testis antigen, AKAP‐4, in PC patients to evaluate the possibility of exploiting AKAP-4 as a target for immunotherapy.
Journal ArticleDOI
A review of clinical experience with paclitaxel extravasations.
Brad L Stanford,Fred Hardwicke +1 more
TL;DR: The goal of this work is to summarize the available reports of paclitaxelExtravasation and assess its vesicant potential and management strategies for extravasation events due to paclitrixel are assessed.
Journal ArticleDOI
Treatment of Hepatic Epithelioid Hemangioendothelioma: Finding Uses for Thalidomide in a New Era of Medicine.
TL;DR: The use of thalidomide as chemotherapy is novel and promising, especially in the setting of a rare vascular liver tumor such as HEH, which involves a 49-year-old female with hepatic masses and metastasis to the lungs with a liver biopsy revealing HEH.
Journal ArticleDOI
The pituitary tumor transforming gene 1 (PTTG-1): An immunological target for multiple myeloma
Maurizio Chiriva-Internati,Raffaele Ferrari,Madhavi Prabhakar,Yuefei Yu,Luigi Baggoni,Jorge H. Moreno,Nicoletta Gagliano,Nicoletta Gagliano,Nicola Portinaro,Marjorie R. Jenkins,Eldo E. Frezza,Fred Hardwicke,Nicholas D'Cunha,Wmartin Kast,Everardo Cobos +14 more
TL;DR: The data suggest that PTTG-1 is aberrantly expressed in multiple myeloma plasma cells, is highly immunogenic and is a suitable target for immunotherapy of multipleMyeloma.